Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma: A technical note

Interventional Neuroradiology

Volumn 16, Issue 1, 2010, Pages 71-76

  Riina, H A ^a   Knopman, J ^a   Greenfield, J P ^a   Fralin, S ^a   Gobin, Y P ^a   Tsiouris, A J ^a   Souweidane, M M ^a   Boockvar, John A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bevacizumab; Brainstem glioma; Intra arterial

Indexed keywords

BEVACIZUMAB; MANNITOL;

ADULT; ANAMNESIS; ANGIOGRAPHY; ARTICLE; BASILAR ARTERY; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CATHETERIZATION; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG DELIVERY SYSTEM; FOLLOW UP; GENERAL ANESTHESIA; GLIOMA; HEMIPARESIS; HUMAN; HYPEREMIA; INTESTINE PERFORATION; LUNG EMBOLISM; MALE; MALIGNANT BRAINSTEM GLIOMA; NERVE PARALYSIS; PERCUTANEOUS THROMBECTOMY; RADIOGRAPHY; RISK ASSESSMENT; SUPERSELECTIVE INTRAARTERIAL CEREBRAL INFUSION; WOUND DEHISCENCE;

EID: 77952317514     PISSN: 11239344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Packer RJ: Brain tumors in children. Arch Neurol 56(4): 421-425, 1999.
2. Freemand CR, Farmer JP: Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40(2): 265-271,1998. (Pubitemid 28114367)
3. Guillamo JS, Monjour A et Al: Brainstem gliomas in adults: prognostic factors and classification. Brain 124: 2528-2539,2001. (Pubitemid 33134940)
4. Salmaggi A, Fariselli L et Al: Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol 255:117-177, 2008.
5. Schild SE, Stafford SL et Al: The results of radiotherapy for brainstem tumors. J Neurooncol 40(2): 171-177, 1998.
6. Vredenburgh JJ, Desjardins A et Al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4): 1253-1259,2007. (Pubitemid 46424067)
7. Riina HA, Fraser JF et Al: Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Therapeut Oncol, in press.
8. Cloughesy TF, Prados MD et Al: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s, 2008.
9. Pope WB, Lai A et Al: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8): 1258-1260,2006. (Pubitemid 43739717)
10. Nghiemphu PL, Green RM et Al: Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 10(3): 355-360, 2008.
11. Lai A, Filka E et Al: Phase II pilot study of bevacizumab in combination with temozolamide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71(5): 1372-1380, 2008.
12. Ananthnarayan S, Bahng et Al: Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88(3): 339-347, 2008.
13. Chen W, Delaloye S et Al: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25(30): 4714-4721,2007. (Pubitemid 350086472)
14. Friedman HS, Prados MD et Al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28): 4733-4740, 2009.
15. Gobin YP, Cloughesy TF et Al: Intraarterial chemotherapy for brain tumors by using a spatiall dose fractionation algorithm and pulsatile delivery. Radiology 218(3): 724-732, 2001.
16. Neuwelt EA, Barnett PA et Al: Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery 17(3): 419-423, 1985.
17. Neuwelt EA, Gilmer-Knight K et Al: Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer 47(2): 174-182,2006. (Pubitemid 44025250)
18. Neuwelt EA, Howieson J et Al: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19(4): 573-582,1986. (Pubitemid 16006308)
19. Neuwelt EA and Dahlborg SA: Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 4(3): 195-207, 1987.
20. Hall WA, Doolittle ND et Al: Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 77(3): 279-284, 2006.